Iberdomide hydrochloride
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Iberdomide hydrochloride
- Molecular weight
- 485.97
- Structure (SMILES)
- Cl.O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1
- cc 220
- cc 220 hydrochloride
- CC-220
- Cc-220 hydrochloride
- iberdomide hydrochloride
- Iberdomide hydrochloride
- IBERDOMIDE HYDROCHLORIDE [USAN]
- Iberdomide hydrochloride [WHO-DD]
- iberdomide hydrochloride usan
- iberdomide hydrochloride who dd
- CAS registry numbers
- 1560678-63-8
- ChEMBL ID
- CHEMBL3989912
- InChIKey
- VVHQVXXPZDALDV-BOXHHOBZSA-N
- PubChem compound IDs
- 72793904
- FDA ingredient codes (UNII)
- 79L3645KFI
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -domide
Open Targets mechanisms
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase modulator
- Action type
- MODULATOR
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Multiple Myeloma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Smoldering Multiple Myeloma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003073
- Subject identifier
- D000075122
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Lupus Erythematosus, Systemic
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007915
- Subject identifier
- D008180
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0018906
- Subject identifier
- D008224
- Condition
- Sarcoidosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0019338
- Subject identifier
- D012507
- Condition identifier
- EFO_0001378
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006611
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018905
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0019338
- Highest recorded phase
- 2
Reported adverse events
- Event
- false positive investigation result
- Reports
- 1
- Reporting signal score
- 7.63874
- NCT02185040
- NCT03161483
- NCT02192489
- NCT02773030
- NCT04855136
- NCT03310619
- NCT03824678
- NCT04464798
- NCT04882163
- NCT04884035
- NCT04776395
- NCT05169515
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 88.18
- Calculated partition coefficient (ALogP)
- 1.86
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 34
- Molecular formula
- C25H28ClN3O5
- Monoisotopic mass
- 485.1717487
- Natural product
- No
- 0003-5700
- 0003-5710
Related records
Trials (54)
- 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects
- 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
- A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Phase 2 Study With CC-220 in Skin Sarcoidosis
- A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects
- A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
- A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
- Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
In development for (9)
- Diffuse large B-cell lymphoma Phase 1
- Follicular lymphoma Phase 1
- Liver disorder Phase 1
- Lymphoma Phase 1
- Non-Hodgkin lymphoma Phase 1
- Plasma cell myeloma Phase 1
- Sarcoidosis Phase 2
- Smoldering plasma cell myeloma Phase 2
- Systemic lupus erythematosus Phase 2